OrthoPediatrics Corp. (KIDS) AI Stock Analysis

OrthoPediatrics Corp. is a medical device company focused on the design, development, and global marketing of implants and devices tailored specifically for pediatric orthopedic conditions. The company's portfolio addresses pediatric trauma and deformity correction, scoliosis and spinal deformities, and sports medicine. Brand offerings include PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, and PediLoc tibia. It has also developed systems such as the RESPONSE Spine systems, Bandloc, Pediatric Nailing Platform, and the ApiFix Mid-C system. The business serves pediatric orthopedic surgeons and caregivers domestically and internationally.

Revenue expanded from $98.0M in FY2021 to $236.3M in FY2025, supported by a 5-year CAGR of 27.2%. In FY2025, revenue grew 15.4%, while gross margin stood at 73.1%. Despite gross margins consistently between 72.6% and 74.9% across the five-year period, operating margin was negative each year, landing at -12.3% in FY2025. Net income was -$39.6M in FY2025, compared to -$37.8M in FY2024 and -$16.3M in FY2021. For the trailing twelve months ended June 30, 2026, revenue totaled $252.7M with quarterly revenue growth of 15.4% year-over-year, alongside an operating margin of -5.8% and a net margin of -15.7%.

As of June 30, 2026, OrthoPediatrics held $45.9M in cash and short-term investments and $91.6M in total debt, resulting in net debt of $45.7M. Shareholders' equity was $343.6M, with a debt-to-equity ratio of 0.27 and a current ratio of 4.78. In FY2025, operating cash flow was -$4.9M, capital expenditures were $11.1M, and free cash flow was -$16.0M. The company's share count increased 23.6% over the 5-year period.

OrthoPediatrics trades at a price-to-sales multiple of 2.3x, which sits below the 4.1x median of its US-listed Healthcare peers. Its EV-to-EBITDA stands at 48.5x, higher than the peer median of 12.0x, while its price-to-book multiple is 1.7x. Over the past year, KIDS rose 23.3%, outperforming the S&P 500 benchmark SPY return of 16.8%. Over a 5-year window, the stock fell 65.1%, compared to an 83.0% gain for SPY.

Wall Street coverage includes 5 Strong Buy, 3 Buy, and 1 Hold ratings, with zero Sell recommendations. The mean price target is $27.22, representing a 24.0% premium over the last close of $21.95 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate revenue of $267.0M and EPS of -$1.09. OrthoPediatrics beat EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for October 27, 2026.

This page is an AI-written research summary of OrthoPediatrics Corp. (KIDS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KIDS income statement, KIDS balance sheet, KIDS key metrics, KIDS analyst forecast, KIDS chart. See the KIDS stock overview for the latest quote and news.